drugset / Trial / NCT02170987

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

NCT02170987

Phase 1 Completed 40 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate if dabigatran has a clinically relevant impact on the cardiac electrophysiology that is manifest as prolongation in QT-interval.

Timeline

Start
2006-03
Primary completion
2006-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg
Subject Dabigatran etexilate Unknown 600 mg
Comparator Moxifloxacin Small molecule

Indications

No indication recorded.